CorMedix, Inc. (CRMD)
-NYSE MKT 0.60 
0.04(7.02%) May 20, 4:00PM EDT
| Prev Close: | 0.64 |
|---|
| Open: | 0.64 |
|---|
| Bid: | 0.58 x 2000 |
|---|
| Ask: | 0.60 x 100 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 0.08 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.60 - 0.66 |
|---|
| 52wk Range: | 0.15 - 1.25 |
|---|
| Volume: | 28,225 |
|---|
| Avg Vol (3m): | 37,977 |
|---|
| Market Cap: | 7.86M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.35 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- CORMEDIX INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- CorMedix Granted Extension of NYSE MKT ListingBusiness Wire(Mon, Apr 22)
- CORMEDIX INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; TraEDGAR Online(Mon, Apr 22)
- CorMedix Notified of NYSE MKT Listing DeficiencyBusiness Wire(Thu, Apr 11)
- CORMEDIX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Notice of Delisting or Failure to SatisEDGAR Online(Thu, Apr 11)
- Biotechs That Tackle Toxicity: Huge Global Market AwaitsMinyanville(Tue, Apr 9)
- Biotechs That Tackle Toxicity: Huge Global Market Awaitsat Minyanville(Tue, Apr 9)
- CORMEDIX INC. FinancialsEDGAR Online Financials(Tue, Apr 2)
- CorMedix's CEO Discusses Q4 2012 Results - Earnings Call Transcriptat Seeking Alpha(Thu, Mar 28)
- CorMedix Reports Year End 2012 Financial ResultsBusiness Wire(Wed, Mar 27)
- CORMEDIX INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed, Mar 27)
- CORMEDIX INC. Files SEC form 10-Q/A, Quarterly ReportEDGAR Online(Wed, Mar 27)
- CORMEDIX INC. Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Fri, Mar 22)
- CORMEDIX INC. Files SEC form 8-K, Other Events, Change in Directors or Principal OfficersEDGAR Online(Wed, Mar 6)
- CORMEDIX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or BylawEDGAR Online(Tue, Feb 19)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
CorMedix Inc., a development stage pharmaceutical and medical device company, focuses on in-license, development, and commercialization of therapeutic products for the treatment of cardiac and renal dysfunction primarily in the dialysis and non-di...
View More